Literature DB >> 7640142

The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects.

N A Alarayyed1, B R Graham, B N Prichard, C C Smith.   

Abstract

1. Aggregation in platelet-rich plasma from normotensive men was induced by adrenaline (0.25-16 microM), ADP (0.25-16 microM), collagen (0.25-8 micrograms ml-1) or serotonin (10 microM) alone, or by previously sub-threshold concentrations of adrenaline (0.03-1 microM) in combination with sub-threshold concentrations of serotonin (2.5 microM), ADP (0.5 microM) or collagen (0.125 micrograms ml-1). The effects of the alpha 1-adrenoceptor blockers naftopidil and doxazosin on platelet aggregation were investigated. 2. The dose-response curves for collagen and ADP were unaffected by either drug. However, naftopidil (40 microM) inhibited serotonin-induced platelet aggregation (23.9%, 95% confidence interval (CI) 10.7 to 37.1%; P < 0.01) and caused a slight shift to the right of the adrenaline dose-response curve with a mean increase in the EC50 value of 0.5 microM (95% CI 0.07 to 0.93 microM; P < 0.05). Doxazosin had no effect on serotonin or adrenaline-induced aggregation. 3. A marked potentiation of the aggregation induced by subthreshold concentrations of adrenaline resulted from the prior addition of low concentrations of ADP, collagen or serotonin. 4. These potentiated responses were inhibited in a dose-dependent manner by naftopidil and to a lesser extent doxazosin. The maximum inhibitions (%) produced by naftopidil (40 microM) on the responses of adrenaline potentiated by ADP were 58.3% (95% CI 36.8 to 79.8%; P < 0.001), serotonin 58.9% (95% CI 40.0 to 77.8%; P < 0.001), and collagen 70.9% (95% CI 52.5 to 89.3%; P < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640142      PMCID: PMC1365123          DOI: 10.1111/j.1365-2125.1995.tb04464.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  THE AGGREGATION OF BLOOD PLATELETS.

Authors:  G V BORN; M J CROSS
Journal:  J Physiol       Date:  1963-08       Impact factor: 5.182

2.  Synergism of platelet-aggregating agents. Role of elevation of cytoplasmic calcium.

Authors:  J A Ware; M Smith; E W Salzman
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

3.  Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation.

Authors:  J A Grant; M C Scrutton
Journal:  Nature       Date:  1979-02-22       Impact factor: 49.962

4.  Effects of prazosin on platelet aggregation and plasma beta-thromboglobulin in essential hypertension.

Authors:  T Ikeda; Y Nonaka; A Goto; M Ishii
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

5.  Characteristics of the synergistic actions of platelet agonists.

Authors:  E M Huang; T C Detwiler
Journal:  Blood       Date:  1981-04       Impact factor: 22.113

6.  Demonstration of human platelet beta-adrenergic receptors using 125I-labeled cyanopindolol and 125I-labeled hydroxybenzylpindolol.

Authors:  M L Steer; D Atlas
Journal:  Biochim Biophys Acta       Date:  1982-04-07

7.  Evidence for functional 5-HT2 receptor sites on human blood platelets.

Authors:  F De Clerck; B Xhonneux; J Leysen; P A Janssen
Journal:  Biochem Pharmacol       Date:  1984-09-01       Impact factor: 5.858

8.  Effect on human platelets of catecholamines at levels achieved in the circulation.

Authors:  N G Ardlie; J A McGuiness; J J Garrett
Journal:  Atherosclerosis       Date:  1985-12       Impact factor: 5.162

9.  Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man.

Authors:  G V Born; M A Kratzer
Journal:  J Physiol       Date:  1984-09       Impact factor: 5.182

Review 10.  Platelet aggregation in hypertension and the effects of antihypertensive treatment.

Authors:  M Nyrop; A J Zweifler
Journal:  J Hypertens       Date:  1988-04       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.